SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling (Q39835229)

15 September 2017

title

SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling (English)

1 reference

15 September 2017

S Haan

1 reference

15 September 2017

S Wüller

1 reference

15 September 2017

J Kaczor

1 reference

15 September 2017

C Rolvering

1 reference

15 September 2017

T Nöcker

1 reference

15 September 2017

I Behrmann

1 reference

15 September 2017

C Haan

1 reference

15 September 2017

language of work or name

English

0 references

publication date

22 June 2009

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

1 reference

15 September 2017

page(s)

3069-3080

1 reference

Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Characterization of murine JAK2V617F-positive myeloproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

A new protein containing an SH2 domain that inhibits JAK kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Structure and function of a new STAT-induced STAT inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

STAT3 is constitutively active in some patients with Polycythemia rubra vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

A family of cytokine-inducible inhibitors of signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

SOCS-1 localizes to the microtubule organizing complex-associated 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Activated Jak2 with the V617F point mutation promotes G1/S phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

The suppressor of cytokine signalling-1 (SOCS-1) gene is overexpressed in Philadelphia chromosome negative chronic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.155

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.155

1 reference

15 September 2017

1 reference